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Abstract
Background: We have previously reported that expression of the Wnt antagonist genes SFRP1 and SFRP5 is frequently
silenced by promoter hypermethylation in breast cancer. SFRP2 is a further Wnt inhibitor whose expression was recently
found being downregulated in various malignancies. Here we investigated whether SFRP2 is also implicated in human
breast cancer, and if so whether SFRP2 promoter methylation might serve as a potential tumor biomarker.
Methods: We analyzed SFRP2 mRNA expression and SFRP2 promoter methylation in 10 breast cell lines, 199 primary
breast carcinomas, 20 matched normal breast tissues and 17 cancer-unrelated normal breast tissues using RT-PCR,
realtime PCR, methylation-specific PCR and Pyrosequencing, respectively. SFRP2 protein expression was assessed by
immunohistochemistry on a tissue microarray. Proliferation assays after transfection with an SFRP2 expression vector
were performed with mammary MCF10A cells. Statistical evaluations were accomplished with SPSS 14.0 software.
Results: Of the cancerous breast cell lines, 7/8 (88%) lacked SFRP2 mRNA expression due to SFRP2 promoter
methylation (P < 0.001). SFRP2 expression was substantially restored in most breast cell lines after treatment with 5-aza-
2'-deoxycytidine and trichostatin A. In primary breast carcinomas SFRP2 protein expression was strongly reduced in 93
of 125 specimens (74%). SFRP2 promoter methylation was detected in 165/199 primary carcinomas (83%) whereas all
cancer-related and unrelated normal breast tissues were not affected by SFRP2 methylation. SFRP2 methylation was not
associated with clinicopathological factors or clinical patient outcome. However, loss of SFRP2 protein expression
showed a weak association with unfavorable patient overall survival (P = 0.071). Forced expression of SFRP2 in mammary
MCF10A cells substantially inhibited proliferation rates (P = 0.045).
Conclusion: The SFRP2 gene is a high-frequent target of epigenetic inactivation in human breast cancer. Its methylation
leads to abrogation of SFRP2 expression, conferring a growth advantage to epithelial mammary cells. This altogether
supports a tumor suppressive function of SFRP2. Although clinical patient outcome was not associated with SFRP2
methylation, the high frequency of this epimutation and its putative specificity to neoplastic cells may qualify SFRP2
promoter methylation as a potential candidate screening marker helping to improve early breast cancer detection.
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Aberrant promoter methylation leading to functional
inactivation of tumor suppressor genes is a well recog-
nized mechanism capable of driving carcinogenesis [1,2].
In human breast cancer numerous genes have been iden-
tified with abolished expression due to 5'-cytosine meth-
ylation within their gene promoter (recently reviewed in
[3]). Typically those genes affect important aspects of nor-
mal growth control, like cell cycle regulation (p16INK4a)
[4], steroid receptor biology (estrogen receptor-α) [5], cell
adhesion (E-cadherin) [6], apoptosis (death-associated
protein (DAP) kinase-1) [7] or extracellular matrix integ-
rity (ITIH5) [8], all of which confers, in case of expression
loss, growth advantages to neoplastic cells. Importantly,
the observation that DNA methylation of the same gene
may occur both in premalignant lesions, such as atypical
hyperplasia of the breast, and in carcinoma [9] suggests
that DNA methylation might serve as ideal biomarker for
early cancer detection or patient risk assessment in clinical
oncology [10]. Thus, identification and validation of epi-
genetically silenced cancer-related genes is of critical
importance in the search of novel tumor biomarkers.
Secreted frizzled-related proteins (SFRPs) constitute a
family of extracellular Wnt signaling antagonists, of which
five members (SFRP1-5) have been identified to date [11].
SFRPs sequester Wnt molecules at the cell surface mem-
brane [12] and by this are recognized as sensitive regula-
tors of the canonical Wnt signaling pathway [13].
Aberrant activation of Wnt signaling has been associated
with the pathogenesis of virtually all human cancers
(reviewed in [14]). In breast tumor tissues, activated Wnt
signaling has been repeatedly observed as determined by
nuclear and cytoplasmic accumulation of β-catenin [15-
18], arguing for a disrupted equilibrium between Wnt and
SFRP expression in this tumor type. In line with this, pre-
vious studies have shown that expression of SFRP genes is
commonly silenced by promoter methylation in human
cancers [19-26]. In breast cancer, SFRP1 and SFRP5 have
been identified as targets of aberrant epigenetic inactiva-
tion to date, and either promoter methylation was found
to be associated with unfavorable patient prognosis
[27,28]. SFRP2 has been previously identified as epige-
netic target in other tumor entities, such as colon [29],
oesophagus [30], bladder [31], stomach [23,24], liver [25]
and lung cancer [32]. Interestingly, in all tumor entities
SFRP2 methylation was detected with a high frequency of
> 50% of cancer patients, ranging from 52% in lung can-
cer to 96% in gastric cancer, which suggests that SFRP2
methylation might potentially be useful as a ubiquitous
pan-tumor marker in cancerous tissues, and possibly also
in body fluids. Consequently, Urakami et al. [22] demon-
strated that of all investigated SFRPs only SFRP2 methyla-
tion proved to be a valuable independent prediction
factor for bladder cancer in urine samples. At the same
time, SFRP2 methylation was found to occur high-fre-
quent in colon cancer (83–90%) [33,19], which may have
forced the establishment of SFRP2 methylation as a prom-
ising sensitive screening marker for the stool-based detec-
tion of colorectal cancer and premalignant lesions [34-
36].
Very recently, Suzuki et al. [37] reported about SFRP2
methylation in human breast cancer, and their study dem-
onstrated an inhibitory effect of SFRP2 on canonical Wnt
signaling in breast cancer cell lines. However, SFRP2
expression analyses in normal and breast carcinoma tis-
sues as well as patient survival analysis in relation to
SFRP2 methylation were not addressed. Our approach
was to investigate SFRP2 expression and promoter meth-
ylation in breast cell lines, primary breast carcinomas and
normal breast tissues, followed by comprehensive statisti-
cal correlation analysis with clinicopathological factors
and patient survival. We also investigated a functional
role of SFRP2 in a breast cell line with regard to growth
behaviour. In summary, our data confirm that the SFRP2
gene is high-frequently inactivated by promoter methyla-
tion in human breast cancer and that loss of SFRP2 expres-
sion confers a growth advantage to mammary epithelial
cells. In addition, we provide evidence that SFRP2 protein
expression is commonly reduced in breast cancer and that
SFRP2 methylation might be a potential biomarker useful
for early detection of this disease.
Methods
Cryoconserved clinical materials
According to a multi-center study design, 20 matched
tumor/macroscopically normal samples of breast cancer
patients (median patient age: 67 years; range 48–86 years)
and 179 unmatched breast carcinomas (median patient
age: 57 years; range 28–96 years) were obtained from
patients treated by primary surgery for breast cancer at the
Departments of Gynecology at the University Hospitals of
Aachen, Jena, Regensburg and Düsseldorf, Germany.
None of the patients had received neo-adjuvant chemo-
therapy. Inclusion criterion for ipsilateral normal breast
tissue was a distance of > 2 cm to the carcinoma margin.
All patients gave informed consent for retention and anal-
ysis of their tissue for research purposes and the Institu-
tional Review Boards of the participating centers approved
the study. The selection of cases was based on availability
of tissue. Cases were not stratified for any known preoper-
ative or pathological prognostic factor. Tumor histology
was determined according to the criteria of the WHO
(2003), while disease stage was assessed according to
UICC [38]. Tumors were graded according to Bloom and
Richardson, as modified by Elston and Ellis [39]. Hor-
mone receptor positivity was defined as an immunoreac-
tivity score (IRS) ≥ 3 [40]. For 136 patients follow-up data
were available with a median time of 64 months (range 1–Page 2 of 19
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zen in liquid nitrogen after surgery. Hematoxylin/Eosin-
stained sections were prepared for assessing the percent-
age of tumor cells; only samples with greater than 70%
tumor cells were selected for analysis. Samples were dis-
solved in lysis buffer followed by DNA isolation using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer's recommendations. For
patient characteristics see additional file 1.
Formalin-fixed, paraffin-embedded (FFPE) clinical 
material
A total of 17 archival FFPE normal breast tissues were
obtained from the Institute of Pathology, University Hos-
pital of the RWTH Aachen, Germany. These patients had
undergone breast reduction surgery without the condition
of cancer. The median age in the cancer-unrelated normal
breast tissue set was 33 years (range 22–61 years). Per
sample, five consecutive sections (each 10 μm) were
deparaffinized and rehydrated in a decreasing alcohol
series prior to DNA extraction by use of the QIAamp DNA
Mini Kit.
SFRP2 protein expression was assessed using a tissue
microarray (TMA) consisting of 125 breast carcinomas,
four ductal carcinomas in situ (DCIS) and 10 normal
breast tissues that have been described previously [41].
The TMA contained one tissue core from non-selected,
FFPE primary breast carcinoma specimens diagnosed
between 1994 and 2002 at the Institute of Pathology, Uni-
versity of Regensburg, Germany. Histological, all tumors
were graded according to Bloom and Richardson, as mod-
ified by Elston and Ellis [39]. Clinical follow-up data were
available for 124 breast cancer patients with a median fol-
low-up period of 80 months (range 5–114 months). All
patients gave informed consent for retention and analysis
of their tissue for research purposes and the Institutional
Review Board of the participating centers approved the
study.
Immunohistochemistry
The TMA was subjected to immunostaining using the
K5007 Kit (DAKO, Hamburg, Germany) following the
manufacturer's instructions. Antigen retrieval was per-
formed by pretreatment in citrate buffer (pH 7) in a
microwave oven (20 min, 200 W). Samples were incu-
bated for 30 min with the primary SFRP2 antibody (rabbit
polyclonal IgG; H-140; 1:75; Santa Cruz Biotechnology,
Santa Cruz, CA), washed, and incubated for 10 min with
the secondary antibody (biotinylated polylink; DAKO).
Diaminobenzidin (DAKO) was used for antibody detec-
tion. In negative controls the primary antibody was omit-
ted. An experienced breast cancer pathologist (N.B.)
scored the immunohistochemical staining according to
the scoring system suggested by Remmele and Stegner
[40]. Feasibility of the antibody for immunohistochemi-
cal analysis of breast tissue has been previously demon-
strated e.g. by Lee et al. [42].
Cell lines
The benign cell lines HMEC and MCF10A as well as the
cancerous breast cell lines BT20, BT474, Hs578T, MCF7,
MDA-MB-231, MDA-MB-453, SKBR3, T47D and ZR75-1
were obtained from the American Type Culture Collection
(Rockville, MA) and cultured as recommended by the ven-
dor.
Reverse transcription (RT-) PCR and semi-quantitative 
realtime PCR
RNA isolation, RT-PCR and SYBR Green I realtime PCR
(Roche Diagnostics, Mannheim, Germany) were per-
formed as described elsewhere [27]. Quality of cDNA was
checked after each preparation by standard RT-PCR using
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
primers that yield an amplification product of 510 bp. To
ensure experiment accuracy, all quantitative measure-
ments were performed in triplicate. Intron-spanning
primer sequences and cycle conditions are given in addi-
tional file 2.
Sodium bisulfite-modification and methylation-specific 
PCR (MSP)
Of the genomic DNA, 1 μg was bisulfite-modified using
the EZ DNA Methylation Kit (Zymo Research, Orange,
CA) according to the manufacturer's recommendations.
The final precipitate was eluted in 20 μl TRIS buffer (10
mM). For MSP, one μl of modified DNA was amplified
using MSP primers (see additional file 2) that specifically
recognized either the unmethylated or methylated gene
promoter sequence after bisulfite-conversion. Each
primer pair mapped to nine cytosine-phosphate-guanine
dinucleotide (CpG) sites in order to specifically discrimi-
nate between methylated and non-methylated DNA. Fur-
ther 11 non-CpG cytosines within the primer pair specific
for methylated DNA and 13 non-CpG cytosines within
the primer pair specific for non-methylated DNA guaran-
teed unequivocal amplification of bisulfite-converted
DNA. Primers defined an amplicon between +19 and
+163 relative to the transcription start site (+1) of the
SFRP2 gene. Reaction volumes of 25 μl contained 1 ×
MSP-buffer [44], 400 nM each of methylation and non-
methylation-specific primers, respectively, and 1.25 mM
of dNTPs. One drop of mineral oil was added to the reac-
tion tube. The PCR was initiated as "Hot Start" PCR at
94°C and held at 80°C before the addition of 1.25 units
Taq DNA polymerase (Promega, Madison, WI). Cycle
conditions were: 95°C for 5 min, 35 cycles of 95°C for 30
s, 60°C for 30 s, 72°C for 40 s and a final extension at
72°C for 5 min. Blood lymphocyte DNA from a healthy
donor was bisulfite-modified to serve as a control for thePage 3 of 19
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cancerous breast cell line BT20 served as control for meth-
ylated alleles. Amplification products were visualized on
3% low range ultra agarose gel (Bio-Rad Laboratories,
Hercules, CA) containing ethidium bromide and illumi-
nated under ultraviolet (UV) light.
Pyrosequencing
Quantitative Pyrosequencing of a SFRP2 promoter frag-
ment was performed by use of a Pyromark ID device,
PyroGoldSQA Reagent Kit and Pyro Q-CpG software
(Biotage, Uppsala, Sweden). Initially, a 291 bp fragment
of the SFRP2 promoter (relative position -28 to +263),
covering the hybridization sites for MSP primers, was
amplified with degenerate primers irrespective of the
methylation status, which assures unbiased DNA amplifi-
cation. To enable single strand preparation the reverse
primer was 5'-biotinylated. Reaction volumes of 50 μl
contained 1 × GoTaq buffer, 2.5 units GoTaq polymerase
(Promega), 2.5 mM of MgCl2, 400 nM of primers, 500 nM
of each dNTP, and 3 μl of bisulfite-converted DNA as tem-
plate. Reactions were initiated as "Hot Start" PCR at 95°C
for 3 min and held at 80°C before addition of Taq
polymerase. Cycle conditions were: 94°C for 3 min, 50
cycles of 94°C for 15 sec, 58°C for 30 sec, 72°C for 30 sec,
and a final extension step at 72°C for 5 min. PCR was car-
ried out in a PTC-200 cycler (Bio-Rad, formerly MJ
Research, Hercules, CA). Prior to sequencing, aliquots of
the amplificate were analyzed on a 2% agarose gel con-
taining ethidium bromide under UV light. Single strand
separation of the remaining amplificate (40 μl) was per-
formed with a PyroMark Vacuum Prep Workstation
(Biotage). Amplificate was immobilized to Streptavidin-
Sepharose HP beads (Amersham Biosciences, Uppsala,
Sweden), washed, denatured and the biotinylated strands
were released into 40 μl of annealing buffer containing
400 nM of forward sequencing primer. Sequencing started
with position +3 (relative to the TSS) and was continued
to position +167, covering a total of 22 sequential CpG
sites. The following sequence represents the SFRP2 pro-
moter sequence that was analyzed by pyrosequencing:
AYGGTTTATTTTGTTTTTTYGGGTYGGAGT TTTTYGGAG
TTGYGYGYGGGTT TGTAGTGTTTYGTTYGYGTTGTTTTT-
TYGGTGTTTYGTTTTTTYGYGTT TTAGTYGTYGGTTGTT
AGTTTTTYGGGGTTTYGAGTYGTATTTAGYGAAGAGAGY
GGGTTYGG. 
Universal bisulfite-converted polymethylated and
unmethylated DNA (Epi Tect Control DNA Set; Qiagen,
Hilden, Germany) served as technical controls for SFRP2
methylation and non-methylation, respectively. Pyrose-
quencing primers are available on request.
5-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA) 
treatment
We plated cells at 3 × 104 cells/cm2 in a six-well plate on
day 0. The demethylating agent DAC (Sigma-Aldrich,
Deisenheim, Germany) was added to a final concentra-
tion of 1 μM in fresh medium on days 1, 2 and 3. Addi-
tionally, 300 nM TSA (Sigma-Aldrich) was added on day
3. Cells were harvested on day 4 for RNA and DNA extrac-
tion. Control cells were incubated without the addition of
DAC or TSA and fresh medium was also supplied on days
1, 2 and 3.
Transient transfection
Cells were seeded at a density of 3 × 104 cells/cm2 and
transfected 24 hours after incubation with 100 ng/cm2 of
plasmid DNA in the following manner: 100 ng of empty
pCMV-hemagglutinin (HA) vector control (Clontech,
Heidelberg, Germany), or 50 ng of pCMV-HA + 50 ng
pCMV-HA/SFRP2, or 50 ng of pCMV-HA + 50 ng
pcDNA3.1-HisA/WNT1, or 50 ng pCMV-HA/SFRP2 + 50
ng pcDNA3.1-HisA/WNT1 [19] applying the FuGENE 6
transfection system (Roche Diagnostics) and a 3:1 trans-
fection ratio according to the manufacturer's instructions.
Proliferation assays
MCF10A cells were transfected in 96-well plates as
described above and an XTT-proliferation assay (Roche
Diagnostics) was performed on day 0, 1, 2 and 3 after
transfection by determining the optical density of the
supernatants at 480 nm minus the optical density of the
supernatants at 690 nm. To enhance experimental accu-
racy, six replicas were seeded. For the colony formation
assay cells were transfected accordingly in six-well plates
and kept for three weeks under selective force of the anti-
biotic G418 (700 μg/ml) (Invitrogen, Carlsbad, CA). After
incubation, colonies were washed with phosphate-buff-
ered saline, fixed and stained for 30 minutes (0.25% crys-
tal violet in 10% formalin/80% methanol), washed three
times with distilled water and photographed.
Statistical methods
Statistical analyses were completed using the software
package SPSS, version 14.0 (SPSS Inc., Chicago, IL). Dif-
ferences were considered significant when P-values were
below 0.05. A two-sided non-parametric Mann-Whitney
U-test and a paired student's t-test were performed to ana-
lyze differences in expression levels. Associations between
metrical variables were determined by a linear regression
analysis. To study statistical associations between clinico-
pathological factors and SFRP2 expression or SFRP2 pro-
moter methylation status contingency-tables and two-
sided Fisher's exact tests were accomplished. Survival
curves were calculated using the Kaplan-Meier method,
with significance evaluated by two-sided log-rank statis-Page 4 of 19
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measured from the day of surgery until tumor-related
death (20.6%, n = 28) and was censored for patients alive
at last contact (69.1%, n = 94), in case of death unrelated
to the tumor (3.7%, n = 5) or when the death cause was
unknown (6.6%, n = 9). Disease-free survival (DFS) (n =
136 for MSP samples) was measured from surgery until
local or distant relapse (36.8%, n = 50) and censored for
patients alive without evidence of relapse at the last fol-
low-up (63.2%, n = 86).
Results
Expression of SFRP2 mRNA is reduced in breast cancer 
cell lines
Initiating our analysis, we used the RT-PCR technique to
evaluate whether SFRP2 mRNA is differentially expressed
in human breast cell lines. SFRP2 mRNA expression was
detectable in the benign cell line HMEC, whilst its expres-
sion was absent in the cancerous cell lines MDA-MB-231,
MCF7, SKBR3, T47D, MDA-MB-453, BT20 and BT474
(Figure 1A). Of the cancerous cell lines only Hs578T
exhibited strong SFRP2 expression. However, SFRP2
expression was also absent in the benign cell line
MCF10A. Additionally, in a commercially available cDNA
of human normal breast tissue (Clontech, Heidelberg,
Germany) SFRP2 was strongly expressed while its expres-
sion was substantially reduced in Clontech's cDNA of pri-
mary breast carcinoma.
Methylation of the SFRP2 promoter in breast cancer cell 
lines
Analysis of the SFRP2 gene promoter on chromosome
4q31 [46] using the genomic DNA information contained
in Ensembl contig ENSG00000145423 [47] revealed a
CpG island (CGI) between base position -818 to +743 rel-
ative to the expected transcription start site (+1), accord-
ing to the CGI definition of Takai and Jones [48]. Further
exploration of this CGI using Methprimer software [49]
identified three regions of particularly high CpG density (-
399 to -151, -6 to +332, and +486 to +685) (Figure 1B).
Since sequence integrity of the first SFRP2 exon was dem-
onstrated to be most essential for efficient RNA transcrip-
tion in a luciferase promoter assay [24] we chose the
central CGI (-6 to +332) for subsequent methylation anal-
ysis by application of the highly specific MSP primers
described by Suzuki et al. [29] and others [24,37]. First, we
assessed SFRP2 promoter methylation in eight cancerous
and two non-cancerous cell lines. Six of the analyzed cell
lines (MCF10A, MDA-MB-231, MCF7, MDA-MB-453,
BT20 and BT474) exhibited a methylated SFRP2 promoter
sequence in the analyzed region (Figure 1C). Two cell
lines (SKBR3 and T47D) showed partial promoter meth-
ylation, since a mixture of unmethylated and methylated
DNA sequence could be detected in the same sample. One
malignant cell line (Hs578T) and benign HMEC cells
revealed solely unmethylated SFRP2 promoter sequence.
This result correlates with the above described finding that
Hs578T and HMEC cells exhibited strong SFRP2 mRNA
expression whereas in all cell lines with aberrant methyla-
tion SFRP2 mRNA expression was absent. Interestingly,
SFRP2 mRNA was not expressed at detectable levels from
unmethyated alleles in SKBR3 and T47D, which may be
due to repressing mechanisms that are codominant to the
effect of promoter methylation in these cells.
Re-expression of SFRP2 mRNA after in vitro DNA 
demethylation
We next asked whether SFRP2 promoter methylation is
functionally associated with loss of SFRP2 mRNA expres-
sion in breast cell lines. To address this question we
treated four representative breast cancer cell lines for four
days with 1 μM of the methyltransferase inhibitor DAC
and one day with 300 nM of the histone deacetylase
inhibitor TSA. As seen in Figure 2A, in three cell lines
(BT20, MCF7 and T47D) the DAC/TSA treatment resulted
in a clear increase of unmethylated SFRP2 promoter
sequence, only in SKBR3 cells there was no visible differ-
ence detectable. Interestingly, BT20 and MCF7 showed
demethylation after the addition of DAC alone, whereas
in T47D cells such effect was only achieved by the combi-
nation of DAC and TSA. Before the treatment, none of the
cell lines showed detectable SFRP2 mRNA expression
(Figure 2B). The treatment with 1 μM DAC alone did not
reverse SFRP2 gene repression in these cells. TSA, in con-
trast, was able to induce some SFRP2 expression in SKBR3
and T47D cells. Importantly, only the combination of
both drugs substantially restored SFRP2 mRNA expres-
sion in all analyzed cell lines.
To further prove that the demethylating treatment did not
result in unspecific upregulation of gene expression, we
determined the expression of the growth promoting gene
cyclin D1, which is a direct read-out gene of active Wnt
signaling [50] and whose expression is commonly ele-
vated in breast cancer [51]. Using realtime PCR we
observed that cyclin D1 mRNA expression was signifi-
cantly reduced (P = 0.029, two-tailed Mann-Whitney U-
test) after the demethylation treatment (43-fold in BT20,
14-fold in SKBR3, 8-fold in T47D and 6-fold in MCF7,
Figure 2C), suggesting that inhibitors of proliferation,
such as SFRPs which are downregulated in breast cancer
cell lines, have been reactivated and were able to block
Wnt signaling in these cells.
Methylation of the SFRP2 promoter in primary breast 
carcinoma and normal breast tissue
In order to answer the question whether SFRP2 promoter
methylation occurs in primary breast carcinoma as well
we analyzed 199 mammary tumor samples by MSP. For
20 breast tumors corresponding tissues of histologicalPage 5 of 19
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SFRP2 expression and promoter methylation in breast cancer cell linesFigure 1
SFRP2 expression and promoter methylation in breast cancer cell lines. (A) SFRP2 mRNA expression in benign and 
malignant cell lines was determined by RT-PCR. All but one malignant cell line (Hs578T) completely lacked SFRP2 mRNA 
expression. Of the two benign breast cell lines (MCF10A and HMEC) only HMEC cells were found to express abundant SFRP2 
mRNA. In a commercially available human normal breast tissue cDNA SFRP2 expression was clearly detectable, while expres-
sion was strongly reduced in a corresponding cDNA of human malignant breast tissue. (B) Genomic structure of the human 
SFRP2 gene on chromosome 4q31. Bioinformatic analysis revealed three CGIs (light blue), located within the SFRP2 promoter 
(left CGI), the 5' untranslated region (UTR; central CGI) and the coding sequence (CDS; right CGI). Methylation of the central 
CGI was explored by MSP. Circles indicate CpG sites; filled circles represent MSP forward (MSP-F) and reverse (MSP-R) 
primer hybridization sites. Indicated positions are related to the transcription start site (+1) initiating the 5'-UTR. (C) MSP was 
performed with bisulfite-treated DNA from the same breast cell lines as in A. DNA bands in lanes labeled with U indicate PCR 
products amplified with primers recognizing unmethylated SFRP2 promoter sequence. DNA bands in lanes labeled with M rep-
resent amplification products with methylation-specific primers. Five out of eight mammary tumor cell lines exhibit complete 
promoter methylation (MDA-MB-231, MCF7, MDA-MB-453, BT20 and BT474), two cell lines show partial SFRP2 methylation 
(SKBR3 and T47D). In Hs578T, only unmethylated SFRP2 promoter sequence could be detected, like it was also found in 
benign HMEC cells. In addition, lymphocyte DNA from a healthy donor did not reveal SFRP2 methylation. GAPDH served as 
cDNA loading control; NTC represents the no template control.
Molecular Cancer 2008, 7:83 http://www.molecular-cancer.com/content/7/1/83normal breast epithelium were available and analyzed in
parallel. Representative results are shown in Figure 3. In
total, 165 of 199 tumor samples (83%) showed SFRP2
promoter methylation as a PCR product could be ampli-
fied with methylation-specific primers (e.g. #103 in Figure
3), and 34 of 199 tumors (17%) showed no evidence of
promoter methylation since exclusive amplification sig-
nals were obtained with primers specific to unmethylated
DNA (e.g. #108 in Figure 3). None of the 20 matched nor-
mal breast tissue samples showed a methylation signal
(e.g. #03 in Figure 3). Tumor samples generally exhibited
also unmethylated promoter sequences due to possible
contamination with small amounts of stromal and
endothelial cells, as has also been described by Suzuki et
al. [19]. To further confirm that SFRP2 promoter methyl-
ation in breast cancer is restricted to malignant tissue, we
analyzed 17 cancer-unrelated normal breast samples.
Again, none of these normal breast tissues (e.g. Figure 3)
harbored detectable SFRP2 methylation.
Correlation of SFRP2 promoter methylation and SFRP2 
mRNA expression in breast cancer cell lines
In order to investigate the association of SFRP2 promoter
methylation with transcriptional silencing in a quantita-
tive manner we assessed in parallel SFRP2 mRNA expres-
sion by realtime PCR and SFRP2 methylation by
quantitative Pyrosequencing in breast cell lines. The tech-
nical controls for Pyrosequencing revealed median meth-
ylation of 4% (unmethylated control) and 90%
(methylated control) in the 22 sequential CpG sites, by
this defining the detection limits of this assay. HMEC cells
exhibited abundant SFRP2 mRNA expression (Δcycle
threshold (CT) GAPDH:SFRP2 = 5.1) (Figure 4A) together
with median SFRP2 methylation of 4%, in contrast to e.g.
BT20 cells which exhibited mean methylation of 83%
together with absence of SFRP2 mRNA expression (ΔCT
GAPDH:SFRP2 = 19.9). Median SFRP2 methylation for
Hs578T, MCF10A, MCF7, MDA-MB-231, SKBR3 and
T47D was 5%, 73%, 73%, 71%, 61% and 42%, respec-
tively. A direct comparison of SFRP2 mRNA expression
and SFRP2 promoter methylation indicates that in breast
cell lines SFRP2 methylation is correlated with loss of
SFRP2 mRNA expression (P < 0.001; Figure 4B). Thus,
when applying an empiric cut-off of > 5% to discriminate
between SFRP2 methylation and non-methylation, all
semi-quantitative results for SFRP2 methylation in breast
cell lines obtained by MSP could be confirmed by the
quantitative Pyrosequencing assay.
Differential expression of SFRP2 protein in primary breast 
cancer
Immunohistochemical analysis was used to investigate
SFRP2 protein expression in normal and malignant breast
tissue. A total of 125 informative breast cancer cases, four
DCIS and 10 normal breast tissues were analyzed. Inten-
sity of immunohistochemical staining was evaluated
using a semi-quantitative IRS [39]. SFRP2 protein was
clearly detectable in 90% (9/10) of normal breast tissue
samples analyzed, as defined by an IRS ≥ 8 (Figure 5C).
The mean expression was determined to be IRS = 7.5
(range 3–8; standard deviation (SD) ± 1.6), and median
expression to be IRS = 8. Expression was predominantly
localized in luminal and basal epithelial cells of the nor-
mal breast while weak expression was detectable in adja-
cent stromal cells. In four DCIS, SFRP2 expression was
slightly reduced (mean IRS = 6.5; range 4–8; SD ± 1.9;
median IRS = 7; Figure 5D, E) with one sample showing
strong reduction (25%, IRS = 4). However, the mean
expression in invasive breast carcinomas was determined
to be IRS = 4.6 (range 0–8; SD ± 2.1) and median expres-
sion to be IRS = 4. Invasive breast carcinomas showed
strongly reduced or complete loss (IRS ≤ 4) of SFRP2
expression in 74% (93/125) of cases (Figure 5F, G). The
SFRP2 expression difference between tumors and normal
breast tissues was statistically significant (P = 0.001).
Correlation of SFRP2 expression and SFRP2 methylation 
with clinicopathological parameters and patient survival
Clinicopathological characteristics of breast cancer
patients were first correlated with SFRP2 protein expres-
sion for descriptive data analysis (Table 1). Loss of SFRP2
expression in tumor tissue (IRS ≤ 4) was not associated
with age at diagnosis, tumor size, histological grade, his-
tological type, estrogen/progesterone receptor status,
Her2 status or expression of p53. A prevalence of more
abundant SFRP2 expression was detected in node negative
breast tumors (P = 0.033). In univariate survival analysis
using log-rank test, loss of SFRP2 protein expression was
not associated with DFS (P = 0.237), but a weak trend was
detected towards reduced OS (P = 0.071) (Figure 6).
SFRP2 promoter methylation in breast carcinomas was
not associated with age at diagnosis, tumor size, lymph
node status, histological grade, histological type, or estro-
gen/progesterone receptor status (Table 2). In univariate
survival analysis, lymph node status, histological grade
and histological type were significantly associated with
DFS; lymph node status and histological grade were sig-
nificantly associated with OS (Table 3). However, SFRP2
methylation was neither associated with DFS (P = 0.192)
nor with OS intervals (P = 0.686).
SFRP2 inhibits proliferation in breast cell lines
Finally, we asked whether SFRP2 influences proliferation
rates in breast cell lines. For gain-of-function experiments
we chose mammary MCF10A cells since these cells were
found to lack SFRP2 mRNA expression. As shown in Fig-
ure 7A, WNT1 overexpressing MCF10A cells notably
increased proliferation compared to cells mock-trans-
fected with empty vector. The equimolar co-transfection
with SFRP2resulted in a decreased proliferation rate asPage 7 of 19
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Global demethylation and histone acetylation restores SFRP2 expressionFigure 2
Global demethylation and histone acetylation restores SFRP2 expression. (A) MSP of four malignant cell lines was 
performed with DNA from either untreated cells, or after treatment with 1 μM DAC, or after treatment with 300 nM TSA, or 
after a combined treatment applying both drugs. In three cell lines (BT20, MCF7, T47D) a promoter demethylating effect could 
be visually detected, since signals indicative of unmethylated SFRP2 promoter arise (BT20, MCF7) or become enhanced (T47D) 
after the combined treatment. In T47D, DAC alone had no detectable demethylating effect on the SFRP2 promoter. (B) 
Expression of SFRP2 mRNA before treatment, or after treatment with 1 μM DAC, or after treatment with 300 nM TSA, or 
after a combined treatment applying both drugs. Treatment with DAC alone was not able to induce SFRP2 expression in all cell 
lines, in contrast to TSA which induced expression in two out of four cell lines (SKBR3 and T47D) previously showing partial 
SFRP2 methylation. However, only combined promoter demethylation and histone reacetylation leads to strong induction of 
SFRP2 mRNA expression in all cell lines. GAPDH served as cDNA loading control. (C) Suppression of Cyclin D1 mRNA expres-
sion after global DNA demethylation of breast cancer cell lines as determined by realtime PCR. Untreated tumor cells (black 
bars) and cells treated with DAC/TSA (grey bars) show significantly different expression levels of Cyclin D1 mRNA (P = 0.029, 
two-sided Mann-Whitney U-test). Expression level of each sample is normalized to its GAPDH expression and related to 
untreated BT20 cells (set to 1).
Molecular Cancer 2008, 7:83 http://www.molecular-cancer.com/content/7/1/83compared to WNT1 alone. Furthermore, SFRP2-transfect-
ants revealed a slightly reduced proliferation rate com-
pared to cells containing empty vector. In order to support
these findings we performed a colony formation assay
and selected transfected clones for three weeks by the anti-
biotic G418. Representative results are shown in Figure
7B. Controls assured the feasibility of this assay, showing
that wild type cells without G418 abundantly form colo-
nies, whereas in the presence of G418 wild type cells fail
to survive. SFRP2-transfected cells exhibit a reduced
number of colonies as compared to mock-transfected
cells. The difference in colony numbers from three inde-
pendent experiments was statistically significant (P =
0.045, two-tailed Mann-Whitney U-test).
Discussion
Aberrant methylation of CpG islands in gene promoters
has been ascertained as a primary mechanism for the inac-
tivation of tumor suppressor genes in human malignan-
cies, including colon and breast cancer (for review see
[3]). Clinically, the identification of genes that are prone
to abnormal methylation and consequently become
downregulated is of critical importance since this is con-
sidered to provide a good source of novel tumor biomar-
kers [52] and potential targets for chemotherapeutics
[53,54]. The family of SFRP genes, functionally acting as
Wnt signaling inhibitors, was recently shown to be a com-
mon target of promoter hypermethylation in numerous
tumor entities [19-26]. In human breast cancer, we have
previously shown that the SFRP1 and SFRP5 promoter is
epigenetically silenced in 61% and 73% of invasive breast
carcinomas, respectively, each of which was associated
with unfavorable patient prognosis [27,28]. We here dem-
onstrate that promoter methylation of SFRP2 is a further
tumor-related alteration in human breast cancer occurring
with even higher incidence.
SFRP2 methylation analysis of primary breast cancer specimensFigure 3
SFRP2 methylation analysis of primary breast cancer specimens. MSP was performed on bisulfite-treated DNA from 
primary invasive breast cancer tissues. MSP results from 19 representative patient samples are shown. DNA bands in lanes 
labeled with U indicate PCR products amplified with primers recognizing the unmethylated SFRP2 promoter sequence. DNA 
bands in lanes labeled with M represent amplified products with methylation-specific primers. In addition, five representative 
normal cancer-unrelated breast tissues (N1 – N5) are shown. DNA from the breast cancer cell line BT20 and lymphocyte 
DNA from a healthy donor (Lyc) served as positive controls for MSP. NTC designates the no template control; T indicates 
tumor tissue; N indicates normal breast tissue.Page 9 of 19
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Molecular Cancer 2008, 7:83 http://www.molecular-cancer.com/content/7/1/83Initiating our study, we found that many breast cancer cell
lines revealed abolished SFRP2 expression presumably
due to methylation of the SFRP2 promoter, since those
cell lines lacking SFRP2 methylation abundantly
expressed SFRP2 mRNA, whereas all cell lines lacking
SFRP2 expression harbored SFRP2 promoter methylation.
A direct coherence between promoter methylation and
loss of RNA expression was shown by a combined DAC/
TSA treatment of breast cancer cell lines, demonstrating
that the SFRP2 gene was effectively demethylated and re-
expressed after the treatment. Furthermore, those cell
lines revealed a significant reduction of cyclin D1 expres-
sion, suggesting reactivation of anti-proliferative genes, of
which SFRP2 is supposed to be a member [19,23,24].
Interestingly, in partially methylated SKBR3 and T47D
cells the sole inhibition of histone deacetylases by TSA led
to restoration of some SFRP2 expression, indicating that
besides DNA methylation in these cells further reversible
chromatin repressing histone modifications may exist.
Since cell lines may acquire de novo genetic and epigenetic
lesions during cultivation [55,56] it is mandatory to inves-
tigate such aberrations in primary tissues as well. To this
end we analyzed SFRP2 promoter methylation in 199
infiltrating breast carcinomas by MSP. We found a high-
frequent incidence of SFRP2 methylation in the tumors
(83%), confirming the recent results from Suzuki et al.
[37], who reported of SFRP2 methylation in 60 of 78
(77%) primary breast carcinomas. Importantly, SFRP2
methylation was independent of relevant clinicopatho-
logical factors, thus being unlikely related to disease stage
or a molecular breast cancer subtype. SFRP2 methylation
was equally prevalent in small sized (pT1) and in larger
sized (pT2-4) breast carcinomas, suggesting it occurs as
early epigenetic aberration in breast tumorigenesis with
no further increase in methylation frequency during
tumor progression. Whether SFRP2 methylation is already
present in benign and earlier premalignant lesions such as
atypical hyperplasia and carcinoma in situ, like it was
recently reported for the 14-3-3-σ gene [9], will be of par-
ticular importance in regard of early breast tumor detec-
tion. Yet, this remains to be determined in a future study.
Interestingly, Suzuki et al. [37] reported that a certain
number of cancer-related normal breast tissues also
showed weak SFRP2 methylation in their study, whereas
in our study none of the normal breast tissues harbored a
methylated SFRP2 promoter, irrespective of whether the
tissue was taken from matched cancer-related or
unmatched cancer-unrelated specimens. Given that no
contaminating tumor cells had been present in their nor-
mal breast tissues this might be due to different locations
of the recruited tissues (i.e. distance to the tumor margin),
and may address a phenomenon that in cancer research is
currently being discussed as "field defect" [57,58]. Evi-
dence of such field defect in breast cancer was brought up
by Yan et al. [59] showing that RASSF1A promoter meth-
ylation in breast carcinoma may progressively diffuse out-
wards to surrounding normal tissue, establishing a sphere
of methylation gradient around the primary tumor.
Recently, such gradient was also detected for RUNX3
methylation [60], which together with RASSF1A methyla-
tion is among the earliest carcinogenetic events in breast
tumor transformation. SFRP2 methylation may be impli-
cated in such field defect in breast cancer, yet dense meth-
ylation of the SFRP2 promoter was restricted to carcinoma
in our study, and thus it may display important clinical
specificity. In bladder cancer, SFRP2 methylation was
shown to represent an independent predictor of malig-
nancy, although in multivariate logistic regression analy-
sis it was not a reliable biomarker because of a limited
sensitivity/specificity due to some extent of methylation
in normal bladder mucosa [22]. In contrast, in faecal DNA
SFRP2 methylation was proven to be a highly promising
screening marker for colorectal cancer [34], even potent to
detect early lesions like adenoma, aberrant crypt foci [35]
and colorectal polyps [36] due to the absence of SFRP2
methylation in normal colonic mucosa. In breast cancer,
the accurate specificity and sensitivity of SFRP2 methyla-
tion remains to be determined by quantitative methods in
a future study, for instance by qMSP (MethyLight) [61] or
the Pyrosequencing technique [62], integrating receiver-
operating characteristic (ROC) curve analyses. This may
potentially lead to a valuable early tumor detection
marker that will ideally be assessable in patients' body flu-
ids like blood serum, plasma or nipple aspirate.
Correlation of SFRP2 promoter methylation and loss of SFRP2 mRNA expression in breast cell linesFigure 4
Correlation of SFRP2 promoter methylation and loss 
of SFRP2 mRNA expression in breast cell lines. (A) 
Realtime PCR of eight breast cell lines revealed abundant 
SFRP2 mRNA expression in benign HMEC and malignant 
Hs578T cells (green bars), whereas in all other investigated 
malignant breast cell lines SFRP2 mRNA expression was sub-
stantially reduced (grey bars). (B) Plotting of SFRP2 mRNA 
expression from the same cell lines (Y-axis) against each 
mean SFRP2 promoter methylation value (X-axis) reveals a 
significant correlation between loss of RNA expression and 
SFRP2 promoter methylation (P = 0.001; Pearson's correla-
tion coefficient r = -0.9241).Page 10 of 19
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SFRP2 protein expression of SFRP2 in normal and malignant breast tissuesFigure 5
SFRP2 protein expression in normal and malignant breast tissues. (A) In the negative control showing normal breast 
tissue the primary SFRP2 antibody was omitted. (B) Scale-up of negative control shown in A. (C) Strong SFRP2 expression in 
ducts and lobules of normal breast tissue (IRS = 12). SFRP2 expression is abundant in epithelial cells, while there is only weak 
expression in stromal cells. (D) Very abundant SFRP2 expression in ductal carcinoma in situ of the breast. (E) Scale-up of spec-
imen shown in D. (F) High-grade tumor exhibiting substantial loss of SFRP2 expression (IRS = 0). (G) Scale-up of specimen 
shown in F. (H) High-grade breast carcinoma with intensive cytoplasmic SFRP2 staining (IRS = 12). Original magnifications: A, F 
= 100×; B, C, G, H = 200×; D = 40×; E = 400×.
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Loss of SFRP2 protein expression in correlation to patient survivalFigure 6
Loss of SFRP2 protein expression in correlation to patient survival. (A) Univariate Kaplan-Meier analysis of patient 
overall survival stratified between SFRP2 expresser (IRS > 4, blue line) and SFRP2 non-expresser (IRS ≤ 4, red line). A weak 
association of loss of SFRP2 protein expression with unfavorable outcome could be detected (P = 0.071, two-sided log-rank 
test). (B) Univariate Kaplan-Meier analysis regarding disease-free patient survival. The visual impression of a clinical impact of 
SFRP2 protein expression loss on breast tumor recurrence was statistically not significant (P = 0.237, two-sided log-rank test). 
Vertical tick marks represent censored patients.
Molecular Cancer 2008, 7:83 http://www.molecular-cancer.com/content/7/1/83Contrasting the view that SFRP2 acts as a tumor suppres-
sor gene, Lee and co-workers [42,63] suggested that SFRP2
exhibits rather an oncogenic property in breast tissue since
this group detected strong upregulation of SFRP2 protein
in canine mammary tumors relative to normal canine
breast tissues. In addition, SFRP2 overexpression in a
human breast cancer cell line (MCF7) inhibited apoptosis
following UV light exposure, while increasing cell-sub-
strate adhesion capacity [64]. It is worthy to note that
these experiments were carried out with a canine homo-
logue of SFRP2 cDNA. However, five lines of evidence
propose a tumor suppressive role of SFRP2 in human
breast carcinogenesis: (1.) Our and another independent
study [37] demonstrate that SFRP2 is very frequently tar-
Table 1: Clinicopathological and immunohistochemical factors in relation to SFRP2 immunoreactivity
SFRP2 immunoreactivity
Variable na IRS 0 – 4 (%) IRS > 4 (%) Rd Pe
Total 125 93 (74) 32 (26)
Clinicopathological factors
Age at diagnosis (median: 57 years; range 29 – 82 years)
< 60 years 69 49 (71) 20 (29) -0.103 0.255
≥ 60 years 55 44 (80) 11 (20)
Tumor sizeb
pT1 42 29 (69) 13 (31) -0.110 0.226
pT2 – 4 81 64 (79) 17 (21)
Lymph node statusb
pN0 62 41 (66) 21 (34) -0.194 0.033
pN1 – 3 59 49 (83) 10 (17)
Histological grade
G1 – G2 67 49 (73) 18 (27) -0.047 0.606
G3 57 44 (77) 13 (23)
Histological type
ductal 98 73 (75) 25 (26) 0.024 0.796
lobular 9 9 (100) 0 (0)
other 14 9 (64) 5 (36)
Immunohistochemistry
Estrogen receptor status
negative (IRSc 0 – 2) 28 20 (71) 8 (29) -0.079 0.424
positive (IRS 3 – 12) 76 60 (79) 16 (21)
Progesterone receptor status
negative (IRSc 0 – 2) 72 55 (76) 17 (24) 0.048 0.611
positive (IRS 3 – 12) 43 31 (72) 12 (28)
Her2
negative (0, 1+) 91 70 (77) 21 (23) 0.110 0.238
positive (2+, 3+) 26 17 (65) 9 (35)
p53
negative (< 5%) 70 53 (76) 17 (24) 0.033 0.724
positive (≥ 5%) 44 32 (73) 12 (27)
aOnly female patients with primary, unilateral, invasive breast cancer were included. bAccording to UICC: TNM Classification of Malignant Tumours 
[38]. cIRS = immunoreactivity score according to Remmele and Stegner [40]. dPearson's correlation coefficient. eFisher's exact test (two-sided). 
Significant P-values are marked in bold face. Percentages may not sum to 100 due to rounding.Page 13 of 19
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mas as compared to normal human breast tissues,
disposing breast cancer to the large number of human
tumor entities for which SFRP2 methylation has already
been described. (2.) We found a strong correlation and
functional association of SFRP2 methylation with loss of
SFRP2 mRNA expression in breast cell lines. (3.) Our
study reveals a common SFRP2 protein loss in human
breast carcinomas with comparable frequency to pro-
moter methylation, notably by applying the identical
SFRP2-antibody that was used for the study of canine
mammary tumors. (4.) We detected a weak trend towards
adverse clinical patient outcome in case of SFRP2 protein
expression loss. (5.) Functional analyses in human breast
[37], gastric [23,24] and colorectal cancer cell lines [19]
revealed a pro-apoptotic and anti-proliferative capacity of
(human) SFRP2 associated with the ability to inhibit acti-
vated Wnt signaling, altogether supporting a tumor sup-
pressive rather than an oncogenic function of this gene.
These discrepancies to canine mammary tumors may
reflect subtle distinctions in the function of structurally
related molecules, or alternative activities of molecules
when expressed in different contexts and organisms. Fur-
thermore, it emphasizes that study results of SFRP2 from
canine breast cancer models may not be generally trans-
ferable to human breast carcinogenesis. In conclusion,
SFRP2 may represent a candidate class II tumor suppres-
sor gene whose altered expression is caused by epigenetic
Table 2: Correlation analysis of SFRP2 promoter methylation with clinicopathological and immunohistochemical patient 
characteristics
SFRP2 promoter
Variable na Unmethylated (%) Methylated (%) Rb Pc
Total 199 34 (17) 165 (83)
Clinicopathological factors
Age at diagnosis
< 60 years 114 24 (21) 90 (79) 0.122 0.091
≥ 60 years 85 10 (12) 75 (88)
Tumor sized
pT1 70 11 (16) 59 (84) -0.013 1.000
pT2 – 4 114 19 (17) 95 (83)
Lymph node statusd
pN0 89 19 (21) 70 (79) 0.129 0.106
pN1 – 3 85 10 (12) 75 (88)
Histological grade
G1 – G2 109 13 (12) 96 (88) -0.139 0.069
G3 76 17 (22) 59 (78)
Histological type
ductal 155 26 (17) 129 (83) -0.057 0.434
lobular 24 1 (4) 23 (96)
other 14 5 (36) 9 (64)
Immunohistochemistry
Estrogen receptor
negative (IRSe 0 – 2) 64 13 (20) 51 (80) 0.084 0.295
positive (IRS 3 – 12) 123 17 (14) 106 (86)
Progesterone receptor
negative (IRSe 0 – 2) 70 14 (20) 56 (80) 0.083 0.304
positive (IRS 3 – 12) 117 16 (14) 101 (86)
aOnly female patients with primary, unilateral, invasive breast cancer were included. bPearson's correlation coefficient. cFisher's exact test (two-
sided). dAccording to UICC: TNM Classification of Malignant Tumours [38]. eIRS = immunoreactivity score [40]. Significant P-values marked in bold 
face.Page 14 of 19
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Class II tumor suppressor genes are particularly interest-
ing drug targets since reversing the block of their gene
expression, e.g. by DNA methyltransferase (DNMT) inhib-
itors or histone deacetylase (HDAC) inhibitors could lead
to tumor regression. Furthermore such a treatment could
be appropriate to eliminate minimal residual cancer dis-
ease after surgical resection of the tumor.
Summarizing, our data demonstrate that SFRP2 is a fre-
quent target of epigenetic inactivation in human breast
cancer leading to downregulation of SFRP2 expression in
mammary tumors. Loss of SFRP2 expression confers a
growth advantage to mammary cells, likely due its ability
to inhibit oncogenic Wnt signaling. Altogether, our data
support the proposed tumor suppressive function of
SFRP2 in normal breast tissue. The high incidence and the
putative specificity of this epimutation may qualify SFRP2
methylation as potential candidate in a screening marker
panel for the early detection of human breast cancer.
Conclusion
Our study on SFRP2 in human breast cancer leads to the
following conclusions: SFRP2 expression is very fre-
Table 3: Univariate survival analysis of clinicopathological and immunohistochemical parameters with SFRP2 promoter methylation
Disease-free survival (DFS) Overall survival (OS)
Variable na Events Pb na Events Pb
Clinicopathological factors
Age at diagnosis
< 60 years 84 33 0.391 83 15 0.414
≥ 60 years 52 18 53 13
Tumor sizec
pT1 51 16 0.059 51 8 0.165
pT2 – 4 82 35 82 20
Lymph node statusc
pN0 59 15 0.008 59 7 0.026
pN1 – 3 66 31 66 18
Histological grade
G1 – G2 72 19 0.003 73 7 0.001
G3 61 32 61 21
Histological type
ductal 109 35 0.009 109 25 0.622
lobular 18 9 18 2
other 9 7 9 1
Immunohistochemistry
Estrogen receptor
negative (IRSd 0 – 2) 47 16 0.644 46 12 0.118
positive (IRS 3 – 12) 84 35 85 16
Progesterone receptor
negative (IRSd 0 – 2) 44 19 0.318 45 12 0.093
positive (IRS 3 – 12) 87 32 86 16
SFRP2 promoter
unmethylated 23 5 0.192 23 5 0.686
methylated 113 45 113 23
aOnly female patients with primary, unilateral, invasive breast cancer were included. bUnivariate log-rank test (two-sided). cAccording to UICC: 
TNM Classification of Malignant Tumours [38]. dIRS = immunoreactivity score [40]. Significant P-values marked in bold face.Page 15 of 19
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methylation, thus conferring growth advantage to neo-
plastic mammary cells. Therefore, SFRP2 may be assigned
a class II tumor suppressor gene in normal breast tissue,
whose block of expression could be reversed by DNA
demethylating (DNMT inhibitors) and histone reacetylat-
ing (HDAC inhibitors) drugs. In contrast to an adverse
prognostic value of SFRP1 or SFRP5 methylation in breast
cancer, failure of SFRP2 methylation as a prognostic
biomarker may be explained by redundant functions of
these closely related SFRP molecules. Alternatively, this
failure could be explained by the likely involvement of
SFRP2 methylation in the early steps of breast carcinogen-
esis, rather than being implicated in the development of
SFRP2 inhibits proliferation in breast epithelial cellsFigure 7
SFRP2 inhibits proliferation in breast epithelial cells. (A) MCF10A cells transfected with empty vector (Mock), SFRP2-
expression vector, WNT1-expression vector or a combination of SFRP2+WNT1-expression vectors were subjected to XTT 
proliferation assays. At three subsequent time points, optical densities (OD) of the supernatants were measured. RNA Expres-
sion of the respective genes was surveyed in parallel 4 days post transfection. GAPDH served as cDNA loading control. SFRP2 
was able to reduce a proliferative effect mediated by WNT1 overexpression, whereas the inhibiting effect of SFRP2 on cells not 
stimulated by WNT1 was only marginal (HA). (B) Long-term inhibiting effects of SFRP2 on the ability to form colonies in 
MCF10A cells. Cells were either transfected with empty vector (Mock) or with SFRP2-expression vector, and after 3 weeks of 
selective pressure (antibiotic G418) fixed, stained and photographed. Non-transfected wild type cells (WT) are shown as con-
trols with (+) and without (-) the application of G418. The difference in colony numbers between mock-transfected and SFRP2-
transfected cells is significant (P = 0.045; two-tailed Mann-Whitney U-test).Page 16 of 19
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Molecular Cancer 2008, 7:83 http://www.molecular-cancer.com/content/7/1/83prognostically adverse tumor subtypes. Nevertheless,
SFRP2 methylation may be potentially useful as a molec-
ular tumor biomarker in a DNA methylation biomarker
based screening assay, as it may display high clinical sen-
sitivity and specificity in detecting breast cancer cells.
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